Prices of key drugs may rise by 25%

Mumbai

The prices of certain life-saving drugs for diseases, including cancer, HIV, haemophilia, diabetes and infections, may go up by 10-25% for both imported and indigenously-produced drugs with the government’s recent tweaking of the levies – removing customs duty waiver as well as imposing excise duty.
Coming days before the Budget, the move is “in contradiction of government’s efforts to improve healthcare” and better access, say experts adding that even drugs which are part of the National List of Essential Medicines (NLEM) have not been spared.

In a notification on January 28, the government withdrew the concessional customs duty on 76 key drugs “in public interest”. Of this, 47 drugs figure in NLEM 2015.

  • Related Posts

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    The officials identified the substance as Alprazolam manufactured illegally at the lab. HYDERABAD: In one of the largest such seizures in recent times, the Narcotics Control Bureau (NCB), Hyderabad, raided…

    Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

    New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices